Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. Older Adults

American Journal of Preventive Medicine

Volumn 44, Issue 4, 2013, Pages 373-381

  Smith, Kenneth J ^a   Wateska, Angela R ^a   Nowalk, Mary Patricia ^a   Raymund, Mahlon ^a   Lee, Bruce Y ^a   Zimmerman, Richard K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERIATRIC CARE; HUMAN; PNEUMOCOCCAL INFECTION; QUALITY ADJUSTED LIFE YEAR; SINGLE DRUG DOSE; UNITED STATES; VACCINATION; VERY ELDERLY; AGE; COST BENEFIT ANALYSIS; ECONOMICS; FACTUAL DATABASE; IMMUNIZATION; PROBABILITY; STATISTICAL MODEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; HUMANS; IMMUNIZATION SCHEDULE; MARKOV CHAINS; MODELS, ECONOMIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 84884196226     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2012.11.035     Document Type: Article

References (41)

1. CDC. 2012 pink book, pneumococcal disease. www.cdc.gov/vaccines/pubs/ pinkbook/downloads/pneumo.pdf.
2. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
3. CDC. Epidemiology and prevention of vaccine-preventable diseases. 8th ed. Washington DC: Public Health Foundation, 2004.
4. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102-6.
5. Fedson D, Musher D. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2004.
6. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Eff?cacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180(1):48-58.
7. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;(1):CD000422.
8. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine eff?cacy among older adults. Neth J Med 2008;66(9):378-83.
9. Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. CDC. Vaccine 2011;29(49):9171-6.
10. Black SB, Shinef?eld HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than f?ve years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21(9): 810-5.
11. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29(12):2287-95.
12. Lexau CA, Lynf?eld R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043-51.
13. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41.
14. CDC. Adult vaccination coverage-U.S.,2010. MMWR Morb Mortal Wkly Rep 2012;61(4):66-72.
15. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307(8):804-12.
16. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008;26(11):1420-31.
17. Arias E. U.S. life tables, 2006. National vital statistics reports; vol. 58, no. 21. Hyattsville MD: National Center for Health Statistics, 2010.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benef?ts of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002;21(3-4):303-11.
20. American Lung Association. Trends in pneumonia and influenza morbidity and mortality. www.lungusa.org/f?nding-cures/our-research/trend-reports/pi- trend-report.pdf. 2010.
21. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griff?n MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S.: a timeseries analysis. Lancet 2007;369(9568):1179-86.
22. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S. Vaccine 2010;28(48):7634-43.
23. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older U.S. adults. Vaccine 2010;28(31):4955-60.
24. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the U.S. J Infect Dis 2012;205(10):1589-92.
25. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281(3):243-8.
26. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Costeffectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138(12):960-8.
27. Centers for Medicare & Medicaid Services. Physician Fee Schedule Search (CPT 90471; Data Year: 2006). www.cms.gov/apps/physicianfee-schedule/ search/search-criteria.aspx.
28. CDC. CDC Vaccine Price List. www.cdc.gov/vaccines/programs/vfc/awardees/ vaccine-management/price-list/downloads/2006.pdf.
29. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14(3):259-65.
30. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule? Med Care 2008;46(4):349-56.
31. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81.
32. U.S. Census Bureau. National Population Estimates for the 2000s. www.census.gov/popest/data/national/asrh/2009/f?les/NC-EST2009-ALLDATA-R-File20. csv.
33. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccineonpneumococcal colonizationamongunvaccinated household members. Clin Infect Dis 2008;47(8):989-96.
34. Hansen J, Black S, Shinef?eld H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9):779-81.
35. ClinicalTrials.gov website. Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA). clinicaltrials.gov/ct2/show/ NCT00744263.
36. Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 2000;68(3):1435-40.
37. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25(20):4029-37.
38. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults. J Infect Dis 2010;201(4):516-24.
39. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9): 1318-25.
40. Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis. Vaccine 2009;27(24): 3159-64.
41. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the U.S. Vaccine 2011;29(18):3398-412.